RUBY

Rubius Therapeutics, Inc.

No insider bought or sold Rubius Therapeutics, Inc. in the last 12 months

$0Bought, 12 mo

$0Sold, 12 mo

Follow RUBY

RUBY over the last year

Prices for RUBY aren't in yet.

RUBY after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

20 insider filings since 2018, newest first

RUBYBuy

David R Epstein · Director

$43K+1.0%Apr 22

RUBYSell

Pablo J Cagnoni · CEO and President

$44K−16.0%Feb 1

RUBYBuy

Flagship Ventures Fund IV General Partner LLC · 10% owner

$6.1M+1.0%Mar 23

RUBYSell

Maiken Keson-Brookes · CLO, Corp. Secretary

$506K−100.0%Mar 15

RUBYSell

David R Epstein · Director

$399K−1.0%Feb 16

RUBYSell

David R Epstein · Director

$1.5M−2.0%Feb 10

RUBYBuy

David R Epstein · Director

$39KMar 17

RUBYSell

Christopher L. Carpenter · Chief Medical Officer

$647K−58.0%Dec 18

RUBYSell

Robert Langer · Director

$64K−100.0%Oct 17

RUBYSell

Christopher L. Carpenter · Chief Medical Officer

$485K−58.0%Sep 18

RUBYSell

Robert Langer · Director

$112K−100.0%Jul 17

RUBYSell

Christopher L. Carpenter · Chief Medical Officer

$670K−58.0%Jun 19

RUBYSell

Robert Langer · Director

$132K−100.0%Apr 17

RUBYSell

Torben Straight Nissen · President

$42KApr 10

RUBYSell

Torben Straight Nissen · President

$252K−1.0%Apr 5

RUBYSell

Christopher L. Carpenter · Chief Medical Officer

$760K−58.0%Mar 19

RUBYSell

Robert Langer · Director

$109K−100.0%Jan 18

RUBYBuy

Catherine A. Sohn · Director

$58KJul 23

RUBYBuy

Francis M Cuss · Director

$230KJul 23

RUBYBuy

Jonathan Symonds · Director

$575KJul 23

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.